TBPH has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
TBPH has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Volatility is a statistical measure of the dispersion of returns for a given security or market index, it shows how the price swings around its mean. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year. In most cases, the higher the volatility, the riskier the security.
As of today (2025-04-06), Theravance Biopharma's Volatility is 31.89%.
For the Biotechnology subindustry, Theravance Biopharma's Volatility, along with its competitors' market caps and Volatility data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Theravance Biopharma's Volatility distribution charts can be found below:
* The bar in red indicates where Theravance Biopharma's Volatility falls into.
The annualized volatility is calculated as following:
σA | = | σM | * | √12 |
= | √ 1/(n-1) ∑(Ri - R')^2 | * | √12 |
Where: σM is the monthly volatility, n is the number of months in the period, Ri is the security's historical monthly returns and R' is the arithmetic mean of monthly returns.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Theravance Biopharma (NAS:TBPH) Volatility Explanation
Volatility is a statistical measure of the dispersion of returns for a given security or market index. It’s often measured as standard deviation or variance of historical returns over a certain period. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year.
Volatility reflects the uncertainty or risk of a security’s value. Generally speaking, a higher volatility suggests a higher risk, because it implies a wider fluctuation around average price. This means the price of the security can change dramatically in either direction within a short period. Conversely, a lower volatility means that the security's price is more steady, which suggests a lower risk.
Another measurement of relative volatility is Beta. Beta is a measure of systematic risk of a security or a portfolio in comparison to the market as a whole. Beta is usually compared to 1. A beta of greater than 1 indicates that the security's price will be more volatile than the market.
Thank you for viewing the detailed overview of Theravance Biopharma's Volatility provided by GuruFocus.com. Please click on the following links to see related term pages.
Rhonda Farnum | officer: SVP, Comm & Medical Affairs | 901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080 |
Eli Samaha | 10 percent owner | ONE WORLD TRADE CENTER, FLOOR 65, NEW YORK NY 10007 |
Richard A Graham | officer: SVP, Development | 901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080 |
Kelly James Connor | director | 901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080 |
Susannah Gray | director | 10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA 92121 |
Brett A. Grimaud | officer: SVP, Gen Counsel and Secretary | 901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080 |
Aziz Sawaf | officer: SVP & Chief Financial Officer | 901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080 |
Rick E Winningham | director, officer: Chief Executive Officer | 901 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080 |
Andrew A. Hindman | officer: SVP, Chief Financial Officer | C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502 |
Weiss Asset Management Lp | 10 percent owner | 222 BERKELEY STREET, 16TH FLOOR, BOSTON MA 02116 |
Andrew M Weiss | 10 percent owner | 222 BERKELEY STREET, 16TH FLOOR, BOSTON MA 02116 |
Wam Gp Llc | 10 percent owner | 222 BERKELEY STREET, 16TH FLOOR, BOSTON MA 02116 |
Philip D Worboys | officer: SVP, Translational Science | 901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080 |
Brett K Haumann | officer: VP-Clinical Develop. | 901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080 |
Deepika Pakianathan | director | 160 BOVET ROAD, SUITE 408, C/O DELPHI VENTURES, SAN MATEO CA 94402 |
From GuruFocus
By PRNewswire • 10-24-2024
By PRNewswire • 07-22-2024
By GuruFocus News • 02-25-2025
By PRNewswire • 02-20-2025
By PRNewswire • 02-12-2025
By PRNewswire • 11-12-2024
By GuruFocus Research • 08-14-2024
By GuruFocus News • 11-05-2024
By GuruFocus News • 02-27-2025
By GuruFocus Research • 08-06-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.